Corvus Pharmaceuticals (CRVS) Cash from Investing Activities Growth (3y) (2018 - 2026)
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Cash from Investing Activities Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.84% |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -11.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.62% |
| Mar 31, 2026 | -222.28% |
| Dec 31, 2025 | 68.72% |
| Sep 30, 2025 | -41.97% |
| Jun 30, 2025 | -103.80% |
| Mar 31, 2025 | 29.38% |
| Dec 31, 2024 | -44.91% |
| Sep 30, 2024 | -46.13% |
| Jun 30, 2024 | -46.56% |
| Mar 31, 2024 | -26.02% |
| Dec 31, 2023 | -91.35% |
| Sep 30, 2023 | 20.86% |
| Jun 30, 2023 | -38.26% |
| Mar 31, 2023 | -45.02% |
| Dec 31, 2022 | -41.69% |
| Sep 30, 2022 | 31.79% |
| Jun 30, 2022 | 96.16% |
| Mar 31, 2022 | -70.04% |
| Dec 31, 2021 | -32.11% |
| Sep 30, 2021 | -47.00% |